BiomX Inc. (PHGE) Reports Q3 Loss of $0.37; Announces Cash and Cash Equivalents of $68.3M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- US stocks set for higher open as AI trade steadies; midterms in focus
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 6% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
- Marvell agrees to acquire Lumentum in all-stock deal valued at $115B
- Cipher Digital posts Q3 revenue of $27M, logs first HPC lease income
- Oracle files to offer $10B in common stock alongside senior notes
- Binance sees spike in withdrawals as exchange returns online after $6.3 billion heist
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
BiomX Reports Third Quarter 2021 Financial Results and Provides Business Update
November 15, 2021 6:00 AM ESTAnnounces Strategic Focus on Cystic Fibrosis and Atopic Dermatitis Programs Based on Potential Proof-of-Concept Clinical Data Readouts in 2022
Cash Runway Now Extended to End of 2023, Well Beyond Key 2022 Data Readouts
FDA Clears BiomX to Begin Phase 1b/2a Trial in Cystic Fibrosis; Trial to Start Imminently
Company Will Host a Conference Call and... More



